20|20 OptimEyes Technologies
20/20 OptimEyes Technologies is a pre-revenue McMaster University spin-out developing a patented mucoadhesive nanoparticle (MNP) drug delivery platform, with lead latanoprost glaucoma and cyclosporine dry eye product candidates targeting reduced dosing frequency and improved compliance.
- Company typePrivate
- Founded2018
- HeadquartersHamilton, Canada
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What 20|20 OptimEyes Technologies does
20|20 OptimEyes Technologies is a Canadian biotechnology spin-out from McMaster University, founded in 2018 and headquartered in Hamilton, Ontario. The company has developed a proprietary MNP (Mucoadhesive Nanoparticles) drug delivery platform that encapsulates small-molecule active pharmaceutical ingredients in micelle structures with a mucoadhesive binding moiety, enabling sustained, localized release on mucosal surfaces. The core technology is protected by granted patents in the United States (Patent No. 10611908), Europe (EP3344232B1), Canada (CA2996910C), and Japan (JP2018529696A). In vivo data show OptimEyes MNPs achieve 6x greater drug concentration on the ocular surface at one week versus standard mucoadhesive nanoparticles, supporting a reduced dosing frequency advantage.
The company's lead product candidate is a latanoprost-based formulation for glaucoma designed for once-weekly dosing, targeting the up to 50% non-compliance rate observed with current daily topical regimens. A secondary candidate addresses dry eye disease with cyclosporine, demonstrated to achieve equivalent efficacy to Restasis in a rat model when dosed once every three days versus twice daily. The MNP platform is positioned as broadly applicable across ophthalmology, respiratory, urogenital, women's health, oncology, and CNS pathologies. The company pursues a dual go-to-market: internal product development for its own pipeline and external licensing collaborations with pharmaceutical partners for novel therapeutics applications.
20/20 OptimEyes operates as a pre-revenue, pre-commercial biotechnology company with a workforce of 1-10 employees. Revenue generation is anticipated through future product sales upon regulatory approval and through licensing fees, milestone payments, and royalty arrangements with strategic partners. The company has received institutional support from McMaster Seed Fund and Innovation Factory, and in September 2025 won the Blue Ticket Competition co-awarded by SpinUp at U of T Mississauga and Merck, providing wet-lab access, mentorship, and research network connectivity. CEO Frances Lasowski leads the organization. No commercial products, pricing, or revenue have been disclosed.
20|20 OptimEyes Technologies firmographics
Firmographics- Name
- 20|20 OptimEyes Technologies
- Legal name
- 20|20 OptimEyes Technologies
- Website
- https://2020optimeyes.ca
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- 20/20 OptimEyes Technologies is a pre-revenue McMaster University spin-out developing a patented mucoadhesive nanoparticle (MNP) drug delivery platform, with lead latanoprost glaucoma and cyclosporine dry eye product candidates targeting reduced dosing frequency and improved compliance.
- Ownership category
- akta.pro rank
20|20 OptimEyes Technologies industry classification
Industry- Product category
- Ophthalmic Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Research and Development in Nanotechnology (541713)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Ocular Drug Delivery Devices (Eye Droppers/Inserts) (HLAHAIAL)
- akta.pro secondary industry
- Ophthalmology Pharmaceuticals (HLAIAAAL)
Keywords
Where 20|20 OptimEyes Technologies is headquartered
LocationHeadquarters
- HQ city
- Hamilton
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
20|20 OptimEyes Technologies business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Internal Product Development: Developing proprietary drug formulations using existing generic therapeutics (e.g., latanoprost for glaucoma) through the MNP platform to create differentiated products with reduced dosing frequency. Revenue will be generated through product sales upon regulatory approval.
- Strategic Partnerships and Licensing: External collaborations with pharmaceutical partners to apply the MNP platform to novel therapeutics. The company offers in vitro and in vivo feasibility and optimization studies for partners. Revenue could come from licensing fees, milestone payments, and royalty arrangements.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
20|20 OptimEyes Technologies product offering
Product offeringCore offering
20|20 OptimEyes Technologies develops and commercializes a proprietary Mucoadhesive Nanoparticles (MNP) drug delivery platform that encapsulates small-molecule drugs in mucoadhesive nanoparticles for sustained, localized release to mucosal surfaces. Its lead product candidate is a latanoprost-based once-weekly glaucoma formulation, and its secondary candidate is a cyclosporine-based dry eye disease formulation. The platform is licensed to pharmaceutical partners and applied across ophthalmology, respiratory, urogenital, women's health, oncology and CNS indications.
Product overview
20|20 OptimEyes Technologies offers the MNP (Mucoadhesive Nanoparticles) Platform as its core technology, a drug delivery system that encapsulates therapeutics in mucoadhesive nanoparticles for sustained, localized delivery to mucosal surfaces. The company's lead product is a latanoprost-based glaucoma treatment (currently in validation), and its secondary product addresses dry eye disease. Both products leverage the same MNP platform technology, which reduces dosing frequency (potentially to once-weekly) while improving bioavailability and patient compliance compared to conventional topical treatments.
Differentiator
Problem solved
Functional benefit
Products and services
- MNP (Mucoadhesive Nanoparticles) Platform A next-generation mucoadhesive drug delivery platform that encapsulates small-molecule drugs in nanoparticles for sustained, localized release to mucosal surfaces, with improved bioavailability and reduced dosing frequency; licensed to pharmaceutical partners and applicable across ophthalmology, respiratory, urogenital, women's health, oncology and CNS indications.
- Glaucoma Treatment (Latanoprost Formulation) Lead product candidate using the MNP platform with latanoprost as the active pharmaceutical ingredient for the treatment of glaucoma, designed for once-weekly dosing to address the up to 50% non-compliance rate with current daily topical eye drop regimens; targeted at chronic glaucoma patients and prescribing ophthalmologists.
- Dry Eye Disease Treatment (Cyclosporine Formulation) Secondary product candidate using the MNP platform with cyclosporine for dry eye disease, offering improved tolerability and once-every-three-days dosing versus the twice-daily regimen of currently approved US treatments (Restasis, Cequa, Xiidra); targeted at patients suffering from dry eye disease with limited efficacy or tolerability issues on existing therapies.
Quantifiable outcome
- 6x greater drug concentration on ocular surface at 1 week compared to standard MNP formulations
- +4 more outcomes
Companies that use 20|20 OptimEyes Technologies
Customer profileSegments3 records
Ideal customer profiles2 records
20|20 OptimEyes Technologies technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
20|20 OptimEyes Technologies partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- SpinUp at U of T MississaugacoreSpinUp is the first wet lab startup incubator at the University of Toronto Mississauga campus. 20/20 OptimEyes won the 2025 Blue Ticket Competition, receiving a free one-year membership providing access to subsidized wet lab space, equipment, entrepreneurship programming and resources in a state-of-the-art facility.
- MerckcoreMerck (known as MSD outside US and Canada) is providing mentorship and guidance from seasoned Merck scientists and business leaders, along with access to U of T's research talent and network. The partnership supports breakthrough innovation in life sciences and aligns with Merck's commitment to groundbreaking health technologies.
- McMaster Universitycore20/20 OptimEyes Technologies is a biotechnology spin-out company from McMaster University located in Hamilton, Canada. The MNP platform technology originated from McMaster research.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
20|20 OptimEyes Technologies competitors and assessment
Company assessmentMarket position
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
20|20 OptimEyes Technologies social profiles
Digital presence20|20 OptimEyes Technologies financial estimates
Financial estimateRevenue estimate
Valuation estimate
20|20 OptimEyes Technologies leadership team
Management profileNumber of profiles
Profiles1 record
20|20 OptimEyes Technologies funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
20|20 OptimEyes Technologies M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about 20|20 OptimEyes Technologies
What does 20|20 OptimEyes Technologies do?
20|20 OptimEyes Technologies develops and commercializes a proprietary Mucoadhesive Nanoparticles (MNP) drug delivery platform that encapsulates small-molecule drugs in mucoadhesive nanoparticles for sustained, localized release to mucosal surfaces. Its lead product candidate is a latanoprost-based once-weekly glaucoma formulation, and its secondary candidate is a cyclosporine-based dry eye disease formulation. The platform is licensed to pharmaceutical partners and applied across ophthalmology, respiratory, urogenital, women's health, oncology and CNS indications.
Is 20|20 OptimEyes Technologies a public or private company?
20|20 OptimEyes Technologies is a private company. It is classified as venture growth investor backed and is currently operating.
When was 20|20 OptimEyes Technologies founded?
20|20 OptimEyes Technologies was founded in 2018. It employs 1 to 10 people.
Where is 20|20 OptimEyes Technologies based?
20|20 OptimEyes Technologies is headquartered in Hamilton, Canada, in the North America region.
How does 20|20 OptimEyes Technologies make money?
Two revenue lines are on record. Internal Product Development is the primary driver. The others are strategic Partnerships and Licensing.
Does 20|20 OptimEyes Technologies have an API?
No public API is recorded for 20|20 OptimEyes Technologies.
What industry is 20|20 OptimEyes Technologies in?
20|20 OptimEyes Technologies's product category is Ophthalmic Pharmaceuticals. Its primary akta.pro industry code is HLAHAIAL, Ocular Drug Delivery Devices (Eye Droppers/Inserts), with a secondary code of HLAIAAAL, Ophthalmology Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.